Overview

A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Status:
Completed

Trial end date:
2019-03-06

Target enrollment:

Participant gender:

Summary

Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 17 years.

Phase:

Phase 2

Details

Lead Sponsor:

Cardinal Health 414, LLC
Navidea Biopharmaceuticals

Treatments:

Dextrans
Technetium Tc 99m Pentetate